We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Sepsis Diagnostics Market Driven by Increasing Prevalence of Bacterial Infections

By LabMedica International staff writers
Posted on 17 Oct 2022
Print article
Image: The global sepsis diagnostics market is expected to surpass USD 1.10 billion by 2027 (Photo courtesy of Pexels)
Image: The global sepsis diagnostics market is expected to surpass USD 1.10 billion by 2027 (Photo courtesy of Pexels)

Sepsis is a potentially fatal condition that occurs when the body's response to an infection causes tissue damage. When the body's infection-fighting processes activate, organs function poorly and abnormally. Sepsis can lead to septic shock, resulting in a significant drop in blood pressure that can cause severe organ damage and death. Sepsis diagnostics include instruments, lab tests, various technologies, and others that are used to diagnose sepsis by examining the patient for signs of infection or organ damage. The global sepsis diagnostics market is expanding due to factors such as the prevalence of the COVID-19 pandemic, an increase in geriatric population, a rise in the prevalence of bacterial infections such as tuberculosis, and increased regulatory approvals for technologically advanced sepsis diagnostics products. As a result, the global sepsis diagnostics market, which was valued at USD 0.65 billion in 2021, is projected to grow at a significant CAGR of 9.60% from 2022 to 2027, to reach USD 1.11 billion.

These are the latest findings of DelveInsight (Las Vegas, NV, USA), a market research firm.

One of the key drivers of the sepsis diagnostics market has been the COVID-19 pandemic. According to the World Health Organization (WHO) data published on 1 July 2022, there were 545,226,550 confirmed cases of COVID-19 across the world. COVID-19 has well-known effects on the respiratory system, with the majority of victims requiring hospitalization for pneumonia of various severity, although almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Therefore, sepsis diagnosis is required to verify or check for signs of any infection or organ damage with the disease. Thus, the surge in COVID-19 pandemic cases has boosted the demand for sepsis diagnostics, and further increase in COVID-19 cases is expected to increase the demand for tools, reagents, and test kits for sepsis detection, resulting in growth of the sepsis diagnostics market.

Based on product type, the instruments & kits segment of the sepsis diagnostics market is expected to record a significant growth during the forecast period. Furthermore, the increased regulatory approvals for technologically advanced sepsis diagnostics products may boost the region's overall sepsis diagnostics market. North America is expected to dominate the global sepsis diagnostics market in 2021 and will continue to dominate the market throughout the forecast period due to rising prevalence of bacterial infections such as tuberculosis and increase in regulatory approvals for technologically-advanced sepsis diagnostics products.

Related Links:
DelveInsight 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more